Thromb Haemost 1985; 54(02): 377-380
DOI: 10.1055/s-0038-1657743
Original Article
Schattauer GmbH Stuttgart

A Standardized Method for Measuring Anti-F VIII:C Inhibitors in Haemophilia A by Coagulation Inhibition in Agarose Gel

J I Jorquera
The Unidad de Inmunología, Hospital “LA FE”, Valencia, Spain
,
E Carmona
The Unidad de Inmunología, Hospital “LA FE”, Valencia, Spain
,
J A Aznar
The Unidad de Inmunología, Hospital “LA FE”, Valencia, Spain
,
A Peiró
The Unidad de Inmunología, Hospital “LA FE”, Valencia, Spain
,
J M Sánchez-Cuenca
The Unidad de Inmunología, Hospital “LA FE”, Valencia, Spain
› Author Affiliations
Further Information

Publication History

Received 21 September 1984

Accepted 07 January 1985

Publication Date:
18 July 2018 (online)

Summary

Antibodies against factor-VIII coagulant activity can appear in haemophilic patients and, although infrequently, can affect individuals not suffering from Haemophilia A. The Oxford and Bethesda methods are presently the most commonly used techniques for measuring these antibodies. Both methods are time-consuming and not suitable for the screening of large risk groups.

An appropriate method for screening these coagulation inhibitors is that described by P. Bird in 1975. It is based on inhibition of the coagulation produced when plasma samples containing inhibitors diffuse in agarose gels mixed with normal platelet rich plasma (PRP). However, this technique is highly dependent on the variability derived from the use of PRP (amount of coagulant factor-VIII, number of platelets, etc.).

In an attempt to avoid these disadvantages, Bird’s method has been modified by using standardized commercial reagents (lyophilized plasma with 100% factor-VIII coagulant activity, purified fibrinogen, and platelet Factor 3) instead of PRP. The sensitivity reaches 0.8 Bethesda units and the correlation with the Bethesda method is r = 0.964, p <0.001. This newly developed method is as simple as Bird’s, and appears to be at least, as accurate and reproducible as the Bethesda method.

 
  • References

  • 1 Rizza CR, Biggs R. The treatment of patients who have factor-VIII antibodies. Br J Haematol 1973; 24: 65-82
  • 2 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thrombos Diathes Haemorrh 1975; 34: 869-871
  • 3 Bird P. Coagulation in an agarose gel and its application to the detection and measurement of factor VIII antibodies. Br J Haematol 1975; 29: 329-340
  • 4 Rainsford SG, Hall A. Detection and measurement of factor VIII antibodies in an agarose gel: A modified method. Br J Haematol 1976; 33: 309
  • 5 Mihalyi E. Physicochemical studies of bovine fibrinogen. IV. Ultraviolet absorption and its relation to the structure of the molecule. Biochemistry 1968; 7: 208-223
  • 6 Aznar JA, Jorquera JI, Peiró A, García I. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in Haemophilia A. Thromb Haemostas 1984; 51: 217-221
  • 7 Sokal RR, Rohlf FJ. Biometry W H Freeman Company. 1969